The "Stop" and "Go" of nicotine dependence: Role of GABA and glutamate

Cold Spring Harbor Perspectives in Medicine

Volumn 3, Issue 6, 2013, Pages

  D'souza, Manoranjan S ^a   Markou, Athina ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; AMINO ACID RECEPTOR BLOCKING AGENT; DOPAMINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; NICOTINE; NICOTINIC RECEPTOR BLOCKING AGENT;

ANIMAL; ANIMAL BEHAVIOR; ARTICLE; BRAIN; CONDITIONING; DRUG EFFECT; HUMAN; LIMBIC SYSTEM; METABOLISM; PSYCHOLOGICAL ASPECT; REINFORCEMENT; SMOKING CESSATION; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CONDITIONING (PSYCHOLOGY); DOPAMINE; EXCITATORY AMINO ACID ANTAGONISTS; GABA AGONISTS; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; LIMBIC SYSTEM; NICOTINE; NICOTINIC ANTAGONISTS; RECEPTORS, GLUTAMATE; REINFORCEMENT (PSYCHOLOGY); SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER;

NICOTIANA TABACUM;

EID: 84878994288     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a012146     Document Type: Article

References (104)

1. Agboola S., McNeill A, Coleman T, Leonardi Bee J. 2010. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction 105: 1362-1380.
2. AmanteaD, Bowery NG. 2004. Reduced inhibitory action of a GABAB receptor agonist on [3H]-dopamine release from rat ventral tegmental area in vitro after chronic nicotine administration. BMC Pharmacol 4: 24.
3. Amantea D., Tessari M, Bowery NG. 2004. Reduced G-protein coupling to the GABAB receptor in the nucleus accumbens and the medial prefrontal cortex of the rat after chronic treatment with nicotine. Neurosci Lett 355: 161-164.
4. Ashby CR Jr, Paul M, Gardner EL, Gerasimov MR, Dewey S.L., Lennon IC, Taylor SJ. 2002. Systemic administration of 1R,4S-4-amino-cyclopent-2-ene-carboxylic acid, a reversible inhibitor of GABA transaminase, blocks expression of conditioned place preference to cocaine and nicotine in rats. Synapse 44: 61-63.
5. Baker D.A., Shen H, Kalivas PW. 2002. Cystine/glutamate exchange serves as the source for extracellular glutamate: Modifications by repeated cocaine administration. Amino Acids 23: 161-162.
6. Baptista M.A., Martin-Fardon R, Weiss F. 2004. Preferential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: Comparison between cocaine and a potent conventional reinforcer. J Neurosci 24: 4723-4727.
7. Benowitz NL. 2010. Nicotine addiction. N Engl J Med 362: 2295-2303.
8. Bespalov A.Y., Dravolina OA, Sukhanov I, Zakharova E, Blokhina E, Zvartau E, Danysz W, van Heeke G, Markou A. 2005. Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue-and schedule-induced reinstatement of nicotine self-administration behavior in rats. Neuropharmacology 49: 167-178.
9. Bormann J. 2000. The "ABC" of GABA receptors. Trends Pharmacol Sci 21: 16-19.
10. Bossert J.M., Gray SM, Lu L, Shaham Y. 2006a. Activation of group II metabotropic glutamate receptors in the nucleus accumbens shell attenuates context-induced relapse to heroin seeking. Neuropsychopharmacology 31: 2197-2209.
11. Bossert J.M., Poles GC, Sheffler-Collins SI, Ghitza UE. 2006b. The mGluR2/3 agonist LY379268 attenuates contextand discrete cue-induced reinstatement of sucrose seeking but not sucrose self-administration in rats. Behav Brain Res 173: 148-152.
12. Brandon T.H., Lazev AB, Juliano LM. 1998. Very delayed smoking relapse warrants research attention. Psychol Rep 83: 72-74.
13. Caggiula A.R., Donny EC, White AR, Chaudhri N, Booth S, Gharib M.A., Hoffman A, Perkins KA, Sved AF. 2001. Cue dependency of nicotine self-administration and smoking. Pharmacol Biochem Behav 70: 515-530.
14. Centers for Disease Control and Prevention. 2011. Current cigarette smoking prevalence among working adults: United States, 2004-2010. MMWR Morb Mortal Wkly Rep 60: 1305-1309.
15. Changeux JP. 2010. Nicotine addiction and nicotinic receptors: Lessons from genetically modified mice. Nat Rev Neurosci 11: 389-401.
16. Chaudhri N., Caggiula AR, Donny EC, Palmatier MI, Liu X, Sved AF. 2006. Complex interactions between nicotine and nonpharmacological stimuli reveal multiple roles for nicotine in reinforcement. Psychopharmacology (Berl) 184: 353-366.
17. Chergui K., Charlety PJ, Akaoka H, Saunier CF, Brunet JL, Buda M., Svensson TH, Chouvet G. 1993. Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo. Eur J Neurosci 5: 137-144.
18. Conn P.J., Pin JP. 1997. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37: 205-237.
19. Corrigall W.A., Coen KM. 1989. Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (Berl) 99: 473-478.
20. Corrigall W.A., Coen KM, Adamson KL, Chow BL, Zhang J. 2000. Response of nicotine self-administration in the rat to manipulations of m-opioid and γ-aminobutyric acid receptors in the ventral tegmental area. Psychopharmacology (Berl) 149: 107-114.
21. Corrigall W.A., Coen KM, Zhang J, Adamson KL. 2001. GABA mechanisms in the pedunculopontine tegmental nucleus influence particular aspects of nicotine self-administration selectively in the rat. Psychopharmacology (Berl) 158: 190-197.
22. D'Souza MS, Markou A. 2011a. Neuronal mechanisms underlying development of nicotine dependence: Implications for novel smoking-cessation treatments. Addict Sci Clin Pract 6: 4-16.
23. D'Souza MS, Markou A. 2011b. Metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP) microinfusions into the nucleus accumbens shell or ventral tegmental area attenuate the reinforcing effects of nicotine in rats. Neuropharmacology 61: 1399-1405.
24. D'Souza MS, Liechti ME, Ramirez-Nino AM, Kuczenski R, Markou A. 2011. The metabotropic glutamate 2/3 receptor agonist LY379268 blocked nicotine-induced increases in nucleus accumbens shell dopamine only in the presence of a nicotine-associated context in rats. Neuropsychopharmacology 36: 2111-2124.
25. Dewey S.L., Brodie JD, Gerasimov M, Horan B, Gardner EL, Ashby CR Jr. 1999. A pharmacologic strategy for the treatment of nicotine addiction. Synapse 31: 76-86.
26. Dravolina O.A., Zakharova ES, Shekunova EV, Zvartau EE, Danysz W., Bespalov AY. 2007. mGlu1 receptor blockade attenuates cue-and nicotine-induced reinstatement of extinguished nicotine self-administration behavior in rats. Neuropharmacology 52: 263-269.
27. Epping-Jordan MP, Watkins SS, Koob GF, Markou A. 1998. Dramatic decreases in brain reward function during nicotine withdrawal. Nature 393: 76-79.
28. Fadda P., Scherma M, Fresu A, Collu M, Fratta W. 2003. Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse 50: 1-6.
29. Fattore L., Spano MS, Cossu G, Scherma M, Fratta W, Fadda P. 2009. Baclofen prevents drug-induced reinstatement of extinguished nicotine-seeking behaviour and nicotine place preference in rodents. Eur Neuropsychopharmacol 19: 487-498.
30. Fenster C.P., Hicks JH, Beckman ML, Covernton PJ, QuickMW, Lester RA. 1999. Desensitization of nicotinic receptors in the central nervous system. Ann NYAcad Sci 868: 620-623.
31. Franklin T.R., Harper D, Kampman K, Kildea-McCrea S, Jens W., Lynch KG, O'Brien CP, Childress AR. 2009. The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend 103: 30-36.
32. Friedman G.D., Siegelaub AB. 1980. Changes after quitting cigarette smoking. Circulation 61: 716-723.
33. Fu Y., Matta SG, Gao W, Brower VG, Sharp BM. 2000. Systemic nicotine stimulates dopamine release in nucleus accumbens: Re-evaluation of the role of N-methyl-D-aspartate receptors in the ventral tegmental area. J Pharmacol Exp Ther 294: 458-465.
34. Fudala P.J., Teoh KW, Iwamoto ET. 1985. Pharmacologic characterization of nicotine-induced conditioned place preference. Pharmacol Biochem Behav 22: 237-241.
35. Gao M., Jin Y, Yang K, Zhang D, Lukas RJ, Wu J. 2010. Mechanisms involved in systemic nicotine-induced glutamatergic synaptic plasticity on dopamine neurons in the ventral tegmental area. J Neurosci 30: 13814-13825.
36. Geisler S., Trimble M. 2008. The lateral habenula: No longer neglected. CNS Spectr 13: 484-489.
37. Geisler S., Wise RA. 2008. Functional implications of glutamatergic projections to the ventral tegmental area. Rev Neurosci 19: 227-244.
38. Geisler S., Zahm DS. 2005. Afferents of the ventral tegmental area in the rat-anatomical substratum for integrative functions. J Comp Neurol 490: 270-294.
39. Giovino GA. 2007. The tobacco epidemic in the United States. Am J Prev Med 33: S318-S326.
40. Grabus S.D., Martin BR, Brown SE, Damaj MI. 2006. Nicotine place preference in the mouse: Influences of prior handling, dose and strain and attenuation by nicotinic receptor antagonists. Psychopharmacology (Berl) 184: 456-463.
41. Guery S., Floersheim P, Kaupmann K, Froestl W. 2007. Syntheses and optimization of new GS39783 analogues as positive allosteric modulators of GABAB receptors. Bioorg Med Chem Lett 17: 6206-6211.
42. Harrison A.A., Gasparini F, Markou A. 2002. Nicotine potentiation of brain stimulation reward reversed by DHβE and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats. Psychopharmacology (Berl) 160: 56-66.
43. Henningfield J.E., Goldberg SR. 1983. Nicotine as a reinforcer in human subjects and laboratory animals. Pharmacol Biochem Behav 19: 989-992.
44. Henningfield J.E., Miyasato K, Jasinski DR. 1985. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J Pharmacol Exp Ther 234: 1-12.
45. Herd N., Borland R, Hyland A. 2009. Predictors of smoking relapse by duration of abstinence: Findings from the International Tobacco Control (ITC) Four Country Survey. Addiction 104: 2088-2099.
46. Hollmann M., Heinemann S. 1994. Cloned glutamate receptors. Annu Rev Neurosci 17: 31-108.
47. Huang Y.H., Bergles DE. 2004. Glutamate transporters bring competition to the synapse. Curr Opin Neurobiol 14: 346-352.
48. Hughes J.R., Gust SW, Skoog K, Keenan RM, Fenwick JW. 1991. Symptoms of tobacco withdrawal: A replication and extension. Arch Gen Psychiatry 48: 52-59.
49. Kalivas P.W., O'Brien C. 2008. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology 33: 166-180.
50. Kenny P.J., Markou A. 2004. The ups and downs of addiction: Role of metabotropic glutamate receptors. Trends Pharmacol Sci 25: 265-272.
51. Kenny P.J., Gasparini F, Markou A. 2003. Group II metabotropic and α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. J Pharmacol Exp Ther 306: 1068-1076.
52. Kenny P.J., Chartoff E, Roberto M, Carlezon WA Jr, Markou A. 2009. NMDA receptors regulate nicotine-enhanced brain reward function and intravenous nicotine self-administration: Role of the ventral tegmental area and central nucleus of the amygdala. Neuropsychopharmacology 34: 266-281.
53. Knackstedt L.A., LaRowe S, Mardikian P, Malcolm R, Upadhyaya H., Hedden S, Markou A, Kalivas PW. 2009. The role of cystine-glutamate exchange in nicotine dependence in rats and humans. Biol Psychiatry 65: 841-845.
54. Koob G.F., Volkow ND. 2010. Neurocircuitry of addiction. Neuropsychopharmacology 35 (Erratum): 1051.
55. Kornetsky C., Esposito RU. 1979. Euphorigenic drugs: Effects on the reward pathways of the brain. Fed Proc 38: 2473-2476.
56. Kosowski A.R., Cebers G, Cebere A, Swanhagen AC, Liljequist S. 2004. Nicotine-induced dopamine release in the nucleus accumbens is inhibited by the novel AMPA antagonist ZK200775 and the NMDA antagonist CGP39551. Psychopharmacology (Berl) 175: 114-123.
57. Le Foll B, Goldberg SR. 2005a. Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans. Trends Pharmacol Sci 26: 287-293.
58. Le Foll B, Goldberg SR. 2005b. Nicotine induces conditioned place preferences over a large range of doses in rats. Psychopharmacology (Berl) 178: 481-492.
59. Levin E.D., Slade S, Wells C, Petro A, Rose JE. 2011. D-Cycloserine selectively decreases nicotine self-administration in rats with low baseline levels of response. Pharmacol Biochem Behav 98: 210-214.
60. Liechti M.E., Markou A. 2007. Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats. Eur J Pharmacol 554: 164-174.
61. Liechti M.E., Lhuillier L, Kaupmann K, Markou A. 2007. Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence. J Neurosci 27: 9077-9085.
62. Malin D.H., Lake JR, Smith TD, Khambati HN, Meyers-Paal R.L., Montellano AL, Jennings RE, Erwin DS, Presley SE, Perales BA. 2006. Bupropion attenuates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl) 184: 494-503.
63. Mansvelder H.D., McGehee DS. 2002. Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol 53: 606-617.
64. Mansvelder H.D., Keath JR, McGehee DS. 2002. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33: 905-919.
65. Mao D., Gallagher K, McGehee DS. 2011. Nicotine potentiation of excitatory inputs to ventral tegmental area dopamine neurons. J Neurosci 31: 6710-6720.
66. Markou A. 2008. Neurobiology of nicotine dependence. Philos Trans R Soc Lond B Biol Sci 363: 3159-3168.
67. Markou A., Koob GF. 1993. Intracranial self-stimulation thresholds as a measure of reward. In Behavioral neuroscience: A practical approach (ed. Sahgal A), pp. 93-115. IRL Press, Oxford.
68. Markou A., Weiss F, Gold LH, Caine SB, Schulteis G, Koob GF. 1993. Animal models of drug craving. Psychopharmacology (Berl) 112: 163-182
69. Martin B.R., Aceto MD. 1981. Nicotine binding sites and their localization in the central nervous system. Neurosci Biobehav Rev 5: 473-478.
70. McBean GJ. 2002. Cerebral cystine uptake: A tale of two transporters. Trends Pharmacol Sci 23: 299-302.
71. McGeehan AJ, Olive MF. 2003. The mGluR5 antagonist MPEP reduces the conditioned rewarding effects of cocaine but not other drugs of abuse. Synapse 47: 240-242.
72. Mombereau C., Lhuillier L, Kaupmann K, Cryan JF. 2007. GABAB receptor-positive modulation-induced blockade of the rewarding properties of nicotine is associated with a reduction in nucleus accumbens DFosB accumulation. J Pharmacol Exp Ther 321: 172-177.
73. Palmatier M.I., Liu X, Donny EC, Caggiula AR, Sved AF. 2008. Metabotropic glutamate 5 receptor (mGluR5) antagonists decrease nicotine seeking, but do not affect the reinforcement enhancing effects of nicotine. Neuropsychopharmacology 33: 2139-2147.
74. Papp M., Gruca P, Willner P. 2002. Selective blockade of drug-induced place preference conditioning by ACPC, a functional NDMA-receptor antagonist. Neuropsychopharmacology 27: 727-743.
75. Paterson N.E., Markou A. 2002. Increased GABA neurotransmission via administration of γ-vinyl GABA decreased nicotine self-administration in the rat. Synapse 44: 252-253.
76. Paterson N.E., Markou A. 2005. The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats. Psychopharmacology (Berl) 179: 255-261.
77. Paterson N.E., Semenova S, Gasparini F, Markou A. 2003. The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl) 167: 257-264.
78. Paterson N.E., Froestl W, Markou A. 2004. The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Psychopharmacology (Berl) 172: 179-186.
79. Paterson N.E., Froestl W, Markou A. 2005. Repeated administration of the GABAB receptor agonist CGP44532 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotineseeking in rats. Neuropsychopharmacology 30: 119-128.
80. Paterson N.E., Vlachou S, Guery S, Kaupmann K, Froestl W, Markou A. 2008. Positive modulation of GABAB receptors decreased nicotine self-administration and counteracted nicotine-induced enhancement of brain reward function in rats. J Pharmacol Exp Ther 326: 306-314.
81. Quick M.W., Lester RA. 2002. Desensitization of neuronal nicotinic receptors. J Neurobiol 53: 457-478.
82. Reid M.S., Fox L, Ho LB, Berger SP. 2000. Nicotine stimulation of extracellular glutamate levels in the nucleus accumbens: Neuropharmacological characterization. Synapse 35: 129-136.
83. Risinger F.O., Oakes RA. 1995. Nicotine-induced conditioned place preference and conditioned place aversion in mice. Pharmacol Biochem Behav 51: 457-461.
84. Rutten K., Van Der Kam EL, De Vry J, Bruckmann W, Tzschentke TM. 2011. The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates conditioned place preference induced by various addictive and non-addictive drugs in rats. Addict Biol 16: 108-115.
85. Schilstrom B., Nomikos GG, Nisell M, Hertel P, Svensson TH. 1998. N-methyl-D-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens. Neuroscience 82: 781-789.
86. Seguela P., Wadiche J, Dineley-Miller K, Dani JA, Patrick JW. 1993. Molecular cloning, functional properties, and distribution of rat brain α7: A nicotinic cation channel highly permeable to calcium. J Neurosci 13: 596-604.
87. Shaham Y., Shalev U, Lu L, De Wit H, Stewart J. 2003. The reinstatement model of drug relapse: History, methodology and major findings. Psychopharmacology (Berl) 168: 3-20.
88. Shiffman S.M., Jarvik ME. 1976. Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology (Berl) 50: 35-39.
89. Shoaib M., Stolerman IP, Kumar RC. 1994. Nicotine-induced place preferences following prior nicotine exposure in rats. Psychopharmacology (Berl) 113: 445-452.
90. Stack NM. 2007. Smoking cessation: An overview of treatment options with a focus on varenicline. Pharmacotherapy 27: 1550-1557.
91. Stolerman I.P., Jarvis MJ. 1995. The scientific case that nicotine is addictive. Psychopharmacology (Berl) 117: 2-10; discussion 14-20.
92. 2+ release from stores. J Neurosci 31: 13546-13561.
93. Tronci V., Balfour DJ. 2011. The effects of the mGluR5 receptor antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) on the stimulation of dopamine release evoked by nicotine in the rat brain. Behav Brain Res 219: 354-357.
94. Tronci V., Vronskaya S, Montgomery N, Mura D, Balfour DJ. 2010. The effects of the mGluR5 receptor antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) on behavioural responses to nicotine. Psychopharmacology (Berl) 211: 33-42.
95. Vlachou S., Guery S, Froestl W, Banerjee D, Benedict J, Finn M.G., Markou A. 2011a. Repeated administration of the GABAB receptor positive modulator BHF177 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine seeking in rats. Psychopharmacology (Berl) 215: 117-128.
96. Vlachou S., Paterson NE, Guery S, Kaupmann K, Froestl W, Banerjee D., Finn MG, Markou A. 2011b. Both GABAB receptor activation and blockade exacerbated anhedonic aspects of nicotine withdrawal in rats. Eur J Pharmacol 655: 52-58.
97. Wang F., Chen H, Steketee JD, Sharp BM. 2007. Upregulation of ionotropic glutamate receptor subunits within specific mesocorticolimbic regions during chronic nicotine self-administration. Neuropsychopharmacology 32: 103-109.
98. Wang L.P., Li F, Shen X, Tsien JZ. 2010. Conditional knockout of NMDA receptors in dopamine neurons prevents nicotine-conditioned place preference. PLoS ONE 5: e8616.
99. Watkins S.S., Epping-Jordan MP, Koob GF, Markou A. 1999. Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol Biochem Behav 62: 743-751.
100. Watkins S.S., Koob GF, Markou A. 2000. Neural mechanisms underlying nicotine addiction: Acute positive reinforcement and withdrawal. Nicotine Tob Res 2: 19-37.
101. Wise RA. 1987. The role of reward pathways in the development of drug dependence. Pharmacol Ther 35: 227-263.
102. Wonnacott S. 1997. Presynaptic nicotinic ACh receptors. Trends Neurosci 20: 92-98.
103. World Health Organization. 2008. WHOReport on the GlobalTobacco Epidemic. World Health Organization, Geneva. Yang K., Buhlman L, Khan GM, Nichols RA, Jin G, McIntoshJM, WhiteakerP, LukasRJ, WuJ.2011. Functional nicotinicacetylcholine receptors containingα6subunitsare on GABAergic neuronal boutons adherent to ventral tegmental area dopamine neurons. J Neurosci 31: 2537-2548.
104. Yararbas G., Keser A, Kanit L, Pogun S. 2010. Nicotine-induced conditioned place preference in rats: Sex differences and the role of mGluR5 receptors. Neuropharmacology 58: 374-382.